0 followers
AdvantiGen has discovered and validated a new Immune-Checkpoint (IC) target on T-cell for Immuno-Oncology; a market forecasted to grow to > $ 155 Billion by 2031. AdvantiGen ADVAN-1 monoclonal antibody (mAbs) program has delivered a set of mAbs modulating the interaction between this new IC target a... Read more
This company has no teams yet